Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Nutriband ( (NTRB) ) is now available.
On July 9, 2025, Nutriband Inc.’s Board of Directors approved an amendment to its Articles of Incorporation to authorize a new series of non-voting shares, the Series A Convertible Preferred Stock. This amendment allows for the issuance of 2,788,678 shares of Series A Preferred Stock, which can be converted into common stock following FDA approval of the company’s transdermal products. The company also announced a preferred stock dividend, with one share of Series A Preferred stock issued for every four shares of common stock held, with a record date of July 25, 2025. This move could potentially enhance shareholder value and position the company favorably in the market.
The most recent analyst rating on (NTRB) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Nutriband stock, see the NTRB Stock Forecast page.
Spark’s Take on NTRB Stock
According to Spark, TipRanks’ AI Analyst, NTRB is a Neutral.
Nutriband’s overall stock score is driven by a strong technical analysis indicating positive momentum and a strategic partnership enhancing brand visibility. However, financial performance challenges and valuation concerns due to negative earnings limit the score.
To see Spark’s full report on NTRB stock, click here.
More about Nutriband
Nutriband Inc. operates in the pharmaceutical industry, focusing on transdermal pharmaceutical products. The company is known for its AVERSA™ abuse deterrent transdermal technology.
Average Trading Volume: 89,960
Technical Sentiment Signal: Buy
Current Market Cap: $89.68M
See more data about NTRB stock on TipRanks’ Stock Analysis page.